Patents Issued in February 16, 2016
  • Patent number: 9259397
    Abstract: A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: February 16, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Lino Tavares, Ihor Shevchuk, Mark Alfonso, Geraldine Marcenyac, Kirti Valia
  • Patent number: 9259398
    Abstract: A composition of bioactive agent-loaded micelles with tissue-targeting properties and methods of using the same are disclosed.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: February 16, 2016
    Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC.
    Inventors: Kyle Klein, Katsuyuki Murase, Jinping Wan, Dariush Davalian
  • Patent number: 9259399
    Abstract: The invention involves methods of inhibiting the cancer cell cycle to make cancer cells more susceptible to chemotherapeutic agents. In particular, inhibition of CDK4 and/or CDK6 inhibits cell cycle progression in cancer cells. When combined with chemotherapy such cell cycle inhibition can effectively treat even aggressive cancer types that are drug-resistant and intractable to most chemotherapies.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: February 16, 2016
    Assignee: Cornell University
    Inventors: Selina Chen-Kiang, Maurizio Di Liberto, Xiangao Huang
  • Patent number: 9259400
    Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: February 16, 2016
    Inventors: Peter Andrew Ferchmin, Vesna Ana Eterovic De Ferchmin, Hector Manuel Maldonado, Khalid El Sayed
  • Patent number: 9259401
    Abstract: The invention disclosed relates to a water-soluble composition having enhanced bioavailability useful for the treatment of depression which comprises a synergistic combination of curcumin, at least an antioxidant, a hydrophilic carrier and a fat. The invention also discloses a process for the preparation of the curcumin composition which comprises the steps of dissolving curcumin, at least one antioxidant, a hydrophilic carrier and a fat in a solvent to form a homogenous mass; warming the resultant mass at a temperature ranging from 25° C. to 60° C. for a period of 4 to 8 hours to obtain a dry wet mass; removing the solvent by evaporation to form dry mass and pulverizing the dry mass to form a fine powder.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: February 16, 2016
    Assignee: OMNIACTIVE HEALTH TECHNOLOGIES LTD.
    Inventors: Jayant Venkatesh Deshpande, Shrinivas Krishnarao Kulkarni
  • Patent number: 9259402
    Abstract: The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; Kennedy's disease (spinal and bulbar muscular atrophy, or SBMA), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein. Treatment of such medical conditions includes administering to an individual suffering from a medical condition describe herein, a therapeutically effective amount of any of the disclosed compounds, their derivatives, or pharmaceutical compositions thereof.
    Type: Grant
    Filed: February 15, 2015
    Date of Patent: February 16, 2016
    Assignee: Allianz Pharmascience Ltd.
    Inventors: Charles Shih, Qian Shi, Hui-Kang Wang
  • Patent number: 9259403
    Abstract: The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: February 16, 2016
    Inventors: Rahul Surana, Mahendra G. Dedhiya
  • Patent number: 9259404
    Abstract: The present invention relates generally to compositions with a health benefit. In particular, the invention relates to the field of brain health, for example brain protection, maintenance of cognitive function, prevention of cognitive decline and prevention of cognitive disorders. A subject matter of the invention is a composition comprising 4-oxo-2-pentenoic acid for use in the treatment or prevention of cognitive decline.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: February 16, 2016
    Assignee: Nestec S.A.
    Inventors: Francia Jacqueline Arce Vera, Bertrand Bourqui, Timo Buetler, Stephane Duboux, Jane Durga, Francis Foata, Philippe Alexandre Guy, Nicolas Page, Serge Andre Dominique Rezzi, Pierre Magistretti, Evelyne Ruchti, Sylvain Lengacher, Igor Allaman
  • Patent number: 9259405
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor diclofenac. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and diclofenac.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: February 16, 2016
    Assignee: INNOVATIVE MED CONCEPTS, LLC
    Inventor: William L. Pridgen
  • Patent number: 9259406
    Abstract: Pharmaceutical composition comprising an antibody specifically recognizing CD38 and melphalan.
    Type: Grant
    Filed: November 27, 2009
    Date of Patent: February 16, 2016
    Assignee: SANOFI
    Inventors: Pascale Lejeune, Patricia Vrignaud
  • Patent number: 9259407
    Abstract: The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a Burkholderia antigen) that generate an effective immune response (e.g., against a bacterial species of the genus Burkholderia) in a subject administered the immunogenic composition. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: February 16, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James R. Baker, Jr., Mark R. Hemmila, Stewart C. Wang, Tarek Hamouda, John J. LiPuma, Jessica Ann Knowlton, Paul E. Makidon, Luz Blanco, Jeffery V. Groom, II, Anna U. Bielinska
  • Patent number: 9259408
    Abstract: The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 16, 2016
    Assignee: Brudy Technology S.L.
    Inventors: Joan Carles Domingo Pedrol, Jose Antonio Villegas Garcia
  • Patent number: 9259409
    Abstract: The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: February 16, 2016
    Assignee: Inceptum Research & Therapeutics, Inc.
    Inventor: Fabrizio G. Mastronardi
  • Patent number: 9259410
    Abstract: The invention provides a method of treating or preventing polycystic ovarian syndrome (PCOS) in a mammal, comprising administering chlorogenic acid and inositol in an amount effective to treat or prevent PCOS in the mammal. In an embodiment of the invention, the method further comprises administering L-cysteine to the mammal.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: February 16, 2016
    Assignee: Oculus Innovative Sciences, Inc.
    Inventor: James J. Schutz
  • Patent number: 9259411
    Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: February 16, 2016
    Inventors: Peter Andrew Ferchmin, Vesna Ana Eterovic De Ferchmin, Hector Manuel Maldonado, Khalid El Sayed
  • Patent number: 9259412
    Abstract: The present invention relates to modafinil or derivatives thereof as a medicine for the treatment of vascular diseases or KCa3.1 channel (Ca activated K channel) mediated diseases and a novel use of the same. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or a derivative of modafinil, or pharmaceutically acceptable salts thereof which relax blood vessels and inhibit KCa3.1 channel currents by increasing intracellular cAMP, a method for treating vascular diseases or KCa3.1 channel-mediated diseases using the composition and a health functional food composition for the prevention or improvement of vascular diseases or the KCa3.1 channel-mediated diseases comprising modafinil or a modafinil derivative compound, or sitologically acceptable salts thereof.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: February 16, 2016
    Assignee: EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION
    Inventors: Suk Hyo Suh, Jae Chul Jung, Sei Kwan Oh
  • Patent number: 9259414
    Abstract: Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: February 16, 2016
    Assignee: Dermira, Inc.
    Inventors: John Allan Statler, Anthony Adrian Shaw, Delphine Caroline Imbert, Jennifer Leigh Nelson, Patricia Andres, Lisa Lynn McQueen, Stephan Xander Mattheus Boerrigter, Jon Gordon Selbo, Mark Christopher Andres
  • Patent number: 9259415
    Abstract: The present disclosure relates to molecules which function as selective modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases and, in particular, CDC42 GTPase, and their use to treat bacterial infection including systemic infection from sources such as Staphylococcus aureus.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 16, 2016
    Assignees: Ball State Innovation Corporation, STC.UNM
    Inventors: Susan A. McDowell, Robert E. Sammelson, Larry A. Sklar, Mark K. Haynes
  • Patent number: 9259416
    Abstract: A drug for the treatment of cerebrovascular disorders associated with insufficient cerebral circulation such as ischemic stroke, which comprises a pharmaceutically effective amount of a pyrazolone compound of structural Formula (I): or a pharmaceutically acceptable salt thereof, or a pseudo-polymorphic form thereof, administered at a controlled dose so that the plasma concentration of unchanged form is kept constant for a predetermined period of time and so that the compound may exhibit a higher effect.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: February 16, 2016
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Satoshi Yuki, Takuma Nakano, Hiroko Suzuki
  • Patent number: 9259417
    Abstract: This invention relates to veterinary compositions for treating and/or preventing fleas or ticks infection or infestation in an animal comprising an isoxazoline active agent of Formula (II): or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: February 16, 2016
    Assignee: MERIAL, INC.
    Inventors: Mark David Soll, Diane Larsen, Susan Mancini Cady, Peter Cheifetz, Izabela Galeska
  • Patent number: 9259418
    Abstract: Pharmaceutical compositions are provided for treatment of Parkinson's disease comprising a pharmaceutically acceptable carrier and a fixed dose combination of two active agents selected from compounds having either neuroprotective or symptomatic effects, or both, in Parkinson's disease patients, wherein the molar ratio of the two compounds is in the range of 1:1 to 1:100. The compositions are formulated for immediate release, controlled release, or both immediate and controlled release.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: February 16, 2016
    Assignee: PHARMATWO B LTD
    Inventors: Itschak Lamensdorf, Yoram Sela
  • Patent number: 9259419
    Abstract: Provided herein are piperidine alkaloids and uses thereof in neurological disorders and physical enhancement applications.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: February 16, 2016
    Assignee: SYNAPSIN PHARMACEUTICALS, INC.
    Inventors: Denis Dorsey, Mark S. Kindy
  • Patent number: 9259420
    Abstract: Drug formulations, methods and their use in treatment of diseases using the free base formulations of tetrandrine family members, especially d-tetrandrine, combined with a pharmaceutical diluent or carrier.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: February 16, 2016
    Assignee: CBA Pharma, Inc.
    Inventor: Ron D. Carroll
  • Patent number: 9259421
    Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: February 16, 2016
    Assignee: Orexo AB
    Inventor: Andreas Fischer
  • Patent number: 9259422
    Abstract: The invention provides method of treating depression comprising administering to a subject compounds having formula 2: or a pharmaceutically acceptable salt or solvate thereof, wherein R, R1, R2, R3, R4 , R5, and X are us defined in the specification.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: February 16, 2016
    Assignee: The University of Bath
    Inventors: John Lewis, Stephen Husbands
  • Patent number: 9259423
    Abstract: The invention relates to a medicament or a method for treating mental disorders, in detail, ADHD comprising lurasidone, or a combination of lurasidone and a D4 receptor agonist.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: February 16, 2016
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Kazuhito Ikeda, Takeo Ishiyama
  • Patent number: 9259424
    Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: February 16, 2016
    Assignee: Aradigm Corporation
    Inventors: David C. Cipolla, James Blanchard
  • Patent number: 9259425
    Abstract: The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: February 16, 2016
    Assignee: Eye Therapies LLC
    Inventor: Gerald Horn
  • Patent number: 9259426
    Abstract: This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R2 is hydrogen, NR?R?, C1-7 alkyl, arylC1-7 alkyl or C3-10 cycloalkyl; R4 is amino, C1-7 alkyl, C2-7 alkenyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted C1-7 alkyl or C3-10 cycloalkyl-C1-7 alkyl; R5 is hydrogen or C1-7 alkyl, or R5 and R4 together with the nitrogen atom to which they are attached form a heterocyclic ring; Y is a single bond, C1-7 alkylene, C2-7 alkenylene or C2-7 alkynylene; R6 is halogen, heteroaryl or aryl; R? and R? are each independently hydrogen, C1-7 alkyl-carbonyl or C1-7 alkyl; provided that R4 is not phenyl substituted with morpholino when R2 is H and R5 is H, and provided that when NR4R5 is piperazinyl, said NR4R5 is either non-substituted or substituted with methyl or acetyl; a pharmaceutically acceptable addition salt, a stereoisomer, a mono- or a di-N-oxide, a solvate or a pro-drug thereof, for the treatment of viral infections.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: February 16, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Ling-Jie Gao, Piet André Maurits Maria Herdewijn, Steven Cesar Alfons De Jonghe, William John Watkins, Lee Shun Chong
  • Patent number: 9259427
    Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: February 16, 2016
    Assignee: Rosemont Pharmaceuticals LTD
    Inventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
  • Patent number: 9259428
    Abstract: A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: February 16, 2016
    Assignee: Cipla Limited
    Inventors: Amar Lulla, Geena Malhotra
  • Patent number: 9259429
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: February 16, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Patent number: 9259430
    Abstract: The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: February 16, 2016
    Assignee: Metabolic Technologies, Inc.
    Inventors: John Rathmacher, John Fuller, Jr., Shawn Baier, Steve Nissen, Naji Abumrad
  • Patent number: 9259431
    Abstract: Long term weight loss can be achieved and maintained with a formulation of over-the-counter life-enhancing dietary supplements. One or more supplements stimulate the release of serotonin within the brain and one or more supplements stimulate the release of cholecystokinin into the bloodstream. The combined potentiating effect of these two mechanisms on satiety enables greater weight loss than that previously achieved by the individual mechanisms acting alone. A third weight loss mechanism can be achieved with the addition of phenylethylamine. Even more effective weight loss formulations can be achieved with the addition of a blue-green algae, such as aphanizomenon flos aqua, to provide a longer lasting weight loss mechanism.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: February 16, 2016
    Inventor: John V. Cappello
  • Patent number: 9259432
    Abstract: Compositions for targeting to a desired region of the brain or spinal cord include a therapeutic compound useful for the treatment of a neurodegenerative disease; a cell penetrating peptide (CPP); and a thermal targeting polypeptide (TTP).
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: February 16, 2016
    Assignee: Parminder J. S. Vig
    Inventors: Parminder J. S. Vig, Drazen Raucher, Scoty Hearst
  • Patent number: 9259433
    Abstract: Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also effective for HSV and HPV infection. Also disclosed are novel viral attachment inhibitors and methods of use.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: February 16, 2016
    Assignee: The Johns Hopkins University
    Inventors: Ru Chih C. Huang, Ibrahim S. Abd-Elazem
  • Patent number: 9259434
    Abstract: A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: February 16, 2016
    Assignee: Endomedix, Inc.
    Inventors: Weiliam Chen, John M. Abrahams
  • Patent number: 9259435
    Abstract: Materials capable of delivering stabilized free radicals to targeted treatment sites. The materials comprise semi-crystalline, hydrolytically degradable polymers that are subjected to ionizing radiation to create stabilized free radicals therein. Upon exposure to oxygen containing aqueous media, the materials generate reactive oxidative species which are useful in biological processes.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: February 16, 2016
    Assignee: W. L. Gore & Associates, Inc.
    Inventors: Tiffany J. Brown, Adam S. Lafleur, Kenneth Mazich, Jeffrey C. Towler, Ji Zhang
  • Patent number: 9259436
    Abstract: The present invention provides a method of treating a skin ailment including administering to a subject in need thereof, a therapeutically effective amount of a composition including (i) a primary diamine; (ii) a secondary aromatic diamine; (iii) a polyisocyanate; and (iv) optionally, a polyol. The present invention also provides a method of forming a skin bandage.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: February 16, 2016
    Assignee: Chesson Laboratory Associates, Inc.
    Inventors: Jerry S. Chesson, Timothy J. Romack, Lance L. Swick, David R. Terry
  • Patent number: 9259437
    Abstract: A scleral lens solution comprising an aqueous mixture that includes sodium, potassium, calcium and magnesium cations and a pH in a range from about 6.5 to about 8.7.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: February 16, 2016
    Assignee: SMM Ventures, LLC
    Inventor: Ralph P Stone
  • Patent number: 9259438
    Abstract: The invention relates to methods to be used in the maturation of ovarian follicles and oocytes. More specifically, the invention concerns the use of inhibitors of the phosphatase PTEN, such as oxovanadate and peroxovanadate complexes, in methods for in vitro and in vivo maturation of follicles and oocytes.
    Type: Grant
    Filed: January 19, 2009
    Date of Patent: February 16, 2016
    Inventor: Kui Liu
  • Patent number: 9259439
    Abstract: Disclosed are dual-phase cement precursor systems and related methods and kits. The cement precursor systems are composed of a first and second discrete phases, at least one of which is aqueous. When combined, the cement precursor phases form a cement that is suitable as a bone graft material for bone repair procedures. In preferred embodiments, the materials are highly biocompatible, osteoinductive, and bioresorbable. A number of different but not mutually exclusive cement chemistries may be employed in the cement precursor systems. For instance, hydrogel-forming polymer cements, carboxyl/calcium cements, or calcium phosphate cements may be employed.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: February 16, 2016
    Assignee: ADA FOUNDATION
    Inventors: Laurence C. Chow, Shozo Takagi
  • Patent number: 9259440
    Abstract: The present invention relates to products and methods for preventing, ameliorating and/or treating infections and other diseases. In one aspect, the products of the present invention relates to compositions comprising germ free colostrum. In another aspect, the products of the present invention relates to compositions comprising synthetically multimerized immunoglobulins. In a third aspect, the products of the present invention relates to compositions comprising germ free colostrum enriched with synthetically multimerized immunoglobulins. The invention also relates to use of said compostions as a pharmaceutical e.g. for prophylactic or ameliorating treatment of infections and other diseases. In addition the invention comprises methods for production of said compositions.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: February 16, 2016
    Assignee: MULTIMERICS ApS
    Inventor: Kirsten Bisgaard-Frantzen
  • Patent number: 9259441
    Abstract: Discloses a novel synergistic herbal composition comprising combination of therapeutically effective amount of Vrun bhavit, Kadalikshar, Apamargkshar, Yavkshar and optionally Gomutrakshar along with pharmaceutical acceptable additives, useful for the treatment of kidney stone and other urinary disorders like inflammation and urinary stent related problems.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: February 16, 2016
    Inventor: Suresh Balkrishna Patankar
  • Patent number: 9259442
    Abstract: A method regenerates specific tissue, preferably mesenchymal tissues like bone, fat, tendon, muscle, cartilage and marrow stroma and hematological tissue (RBC, WBC, platelets, lymphocytes, hematological stem cells (HSC), endothelial progenitor cells (EPC) etc.). A method for reconstructing, regenerating, rejuvenating or reinforcing a damaged or diseased tissue in a mammal subject, and preferably a human patient, uses a (regenerated) tissue obtained by this method.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: February 16, 2016
    Inventor: Pierre Philippart
  • Patent number: 9259443
    Abstract: Compositions and methods for generating platelets and methods of use thereof are disclosed.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: February 16, 2016
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Mortimer Poncz, Mitchell Weiss, Paul Gadue, Deborah French
  • Patent number: 9259444
    Abstract: The subject of the present invention is a bioactive cell homogenate produced from cells belonging to the MIC-1 stem cell line derived from growing deer antlers (Cervidae) deposited at the DSMZ under the accession DSM ACC2854, a method of producing and using it. The present invention also encompasses a pharmaceutical or cosmetic composition containing the above-mentioned homogenate.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: February 16, 2016
    Assignee: STEM CELLS SPIN S.A.
    Inventors: Wojciech Dziewiszek, Marek Cegielski, Marek Bochnia
  • Patent number: 9259445
    Abstract: The present invention refers to an Integrated Implant System constituted as a gel-matrix-cells integrated system, that allows providing implants in a brief time period, for covering a great skin extension to be treated, with a successful acceptance in patients with burns, chronic damage or wound skin, needing of a skin grafting.
    Type: Grant
    Filed: June 7, 2007
    Date of Patent: February 16, 2016
    Assignees: UNIVERSIDAD TECNICA FEDERICO SANTA MARIA, UNIVERSIDAD DE VALPARAISO, FUNDACION INSTITUTO DE SEGURIDAD DEL TRABAJO
    Inventors: Manuel Eduardo Young Anze, Cristian Andrés Acevedo Gutiérrez, Fernando Antonio Albornoz Marquez, Caroline Ruth Weinstein Oppenheimer, Alexis Roobins Aceituno Alvarez, Donald Irving Brown Gonzalez, Sergio Miguel Tapia Murua
  • Patent number: 9259446
    Abstract: Compositions and methods for controlling molluscs, members of the Gastropoda and Bivalvia classes which includes but is not limited to lactones, lactams, carbamates, amides, and/or carboxylic acid containing compounds as active ingredients and/or compounds derived from Pseudomonas and/or Erwinia. Also provided are methods and compositions for increasing the efficacy of chemical and biological control for invasive molluscs in open waters, power plants, and drinking water treatment facilities under coldwater conditions.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: February 16, 2016
    Assignee: MARRONE BIO INNOVATIONS, INC.
    Inventors: Ratnakar Asolkar, Sarahann Rackl, Huazhang Huang, Marja Koivunen, Pamela Marrone
  • Patent number: 9259447
    Abstract: The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: February 16, 2016
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Rémy Burcelin, Didier Carcano, Pierre Desreumaux, Sampo Lahtinen, Nina Rautonen, Heli Putaala, Kirsti Tiihonen, Rodolphe Barrangou